---
title: "enGene Therapeutics (ENGN) stock: news and investor profile"
url: "https://aibio.space/companies/engene-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "enGene Therapeutics Inc. (NASDAQ: ENGN), Canada. The directory classifies it as Non-viral genetic medicines."
---

ENGN enGene Therapeutics Inc. NASDAQ · Canada

# enGene Therapeutics (ENGN) news

Distress · 2026-06-15

## [enGene Therapeutics cuts workforce by about 50% in restructuring to preserve cash](https://aibio.space/news/engene-therapeutics-cuts-workforce-about-50-percent-restructuring/)

enGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand.

## Latest enGene Therapeutics news

1. 2026-06-15 Distress [enGene cuts about 50% of workforce, reports $285.2 million in cash](https://aibio.space/news/engene-cuts-about-50-percent-workforce-reports-285-2-million-cash/) The bladder cancer gene therapy developer stopped enrollment in three study cohorts to conserve cash. It plans to start its BLA filing in the second half of 2026.
2. 2026-03-09 Financings [enGene Holdings (now enGene Therapeutics) sets up $100,000,000 stock program](https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/) The company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold.
3. 2026-01-21 Debt Financing [enGene Holdings (now enGene Therapeutics) expands Hercules loan to up to $125 million](https://aibio.space/news/engene-holdings-now-engene-therapeutics-expands-hercules-loan-up-125/) The Second Amendment draws $25 million at closing to refinance existing term loans. Further tranches depend on milestones.

## enGene Therapeutics at a glance

- **Ticker**: ENGN

- **Listing**: NASDAQ

- **Country**: Canada

- **Cash, Jul 31, 2026**: $266.3 million

### Related companies

- [Waverley Pharma](https://aibio.space/companies/waverley-pharma/) TSXV: WAVE
- [Medicure](https://aibio.space/companies/medicure/) TSXV: MPH
- [Revive Therapeutics](https://aibio.space/companies/revive-therapeutics/) CSE: RVV
- [Milestone Pharmaceuticals](https://aibio.space/companies/milestone-pharmaceuticals/) NASDAQ: MIST
- [Core One Labs](https://aibio.space/companies/core-one-labs/) OTC: CLABF
- [Resverlogix](https://aibio.space/companies/resverlogix/) TSX: RVX
- [Avricore Health](https://aibio.space/companies/avricore-health/) TSXV: AVCR
- [NervGen Pharma](https://aibio.space/companies/nervgen-pharma/) NASDAQ: NGEN

### Also on NASDAQ

- [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) MGX
- [Electra Therapeutics](https://aibio.space/companies/electra-therapeutics/) ETRA
- [First Tracks Biotherapeutics](https://aibio.space/companies/first-tracks-biotherapeutics/) TRAX
- [Vistagen Therapeutics](https://aibio.space/companies/vistagen-therapeutics/) VTGN
- [IN8bio](https://aibio.space/companies/in8bio/) INAB
- [Lexaria Bioscience](https://aibio.space/companies/lexaria-bioscience/) LEXX

## enGene Therapeutics annual financials

| Line | FY ended Oct 31, 2025 | FY ended Oct 31, 2024 |
|---|---|---|
| Research and development | [$94.5 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) | [$38.3 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) |
| Net income (loss) | [-$117.3 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) | [-$55.1 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) |
| Cash from operations | [-$99.2 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) | [-$48.3 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) |
| Cash and equivalents | [$50.2 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312526384383/) | [$173.0 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) |
| Short-term investments | [$143.6 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312526384383/) | [$65.3 million](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/) |

Latest balance sheet, Jul 31, 2026 (10-Q): cash and equivalents $41.0 million, plus short-term investments of $225.3 million, $266.3 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about enGene Therapeutics

What is the ticker symbol of enGene Therapeutics?

enGene Therapeutics Inc. trades under the ticker ENGN on NASDAQ.

Where is enGene Therapeutics listed?

enGene Therapeutics Inc. is listed on NASDAQ.

What is the SEC CIK of enGene Therapeutics?

The SEC Central Index Key (CIK) for enGene Therapeutics Inc. is 1980845. Its filings are on SEC EDGAR.

How many shares does enGene Therapeutics have outstanding?

67,016,316 shares as of 2026-09-02, per the cover page of its 10-Q filed 2026-09-08.

Which country or territory is enGene Therapeutics listed under?

Our directory records enGene Therapeutics Inc. under Canada.

What does enGene Therapeutics do?

Our directory classifies enGene Therapeutics Inc. as: Non-viral genetic medicines. This is a directory classification, not a description of the pipeline.

What is the ISIN of enGene Therapeutics?

The ISIN recorded for enGene Therapeutics Inc. is CA29286X1015.

Does aibio.space cover enGene Therapeutics?

aibio.space lists enGene Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is enGene Therapeutics incorporated?

SEC records list its state or country of incorporation as Z4.

Is enGene Therapeutics profitable?

enGene Therapeutics Inc. reported a net loss of $117.3 million for the fiscal year ended Oct 31, 2025, and used $99.2 million of cash in operations, per its annual report to the SEC.

How much does enGene Therapeutics spend on research and development?

$94.5 million in the fiscal year ended Oct 31, 2025, per its annual report.

How much cash does enGene Therapeutics have?

$266.3 million in cash and short-term investments at Jul 31, 2026, per its 10-Q.

What is the latest enGene Therapeutics (ENGN) stock news?

Our latest story on enGene Therapeutics, dated Jun 15, 2026: "enGene Therapeutics cuts workforce by about 50% in restructuring to preserve cash". enGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand. [Source](https://aibio.space/news/engene-therapeutics-cuts-workforce-about-50-percent-restructuring/).

What is enGene Therapeutics's latest stock offering or financing news?

Our latest financing story, dated Mar 9, 2026: "enGene Holdings (now enGene Therapeutics) sets up $100,000,000 stock program". The company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold. [Source](https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/).

Who were the underwriters or placement agents on enGene Therapeutics's offering?

From our story: Leerink is the sales agent and may sell by any method that counts as an at-the-market offering under the securities rules, or by any other method the law permits. [Source](https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/).

## Investor discussion: enGene Therapeutics

Members talk about enGene Therapeutics (ENGN). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at enGene Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-06-15 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-ex99_1.htm)
2. 2026-03-09 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1980845/000119312526097546/engn-20260309.htm)
3. 2026-01-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/engn-20260120.htm)
4. 2025-11-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1980845/000119312525277833/d34778d424b5.htm)
5. 2024-12-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1980845/000095017024138766/424b5_engene_pro_supp_at.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ENGN on TradingView](https://www.tradingview.com/symbols/NASDAQ-ENGN/).

## SEC filings and registration

- **SEC name**: enGene Therapeutics Inc.

- **CIK**: 1980845

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: ENGN (Nasdaq), ENGNW (Nasdaq)

- **State or country of incorporation**: Z4

- **Fiscal year ends**: October 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 4868 RUE LEVY, SUITE 220, SAINT-LAURENT

- **Phone**: (514) 332-4888

- **Shares outstanding**: 67,016,316 as of 2026-09-02 (10-Q filed 2026-09-08)

- **Former names**: enGene Holdings Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1980845/000119312526384383/engn-20260731.htm) filed 2026-09-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/engn-20260908.htm) filed 2026-09-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/engn-20260811.htm) filed 2026-08-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1980845/000119312526307795/engn-20260717.htm) filed 2026-07-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/engn-20260715.htm) filed 2026-07-16
- [10-Q](https://www.sec.gov/Archives/edgar/data/1980845/000119312526270386/engn-20260430.htm) filed 2026-06-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-20260613.htm) filed 2026-06-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/engn-20260609.htm) filed 2026-06-10

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001980845), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

enGene Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ENGN, recorded under Canada. The directory classifies it as Non-viral genetic medicines. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: enGene Therapeutics Inc.

- **Ticker**: ENGN

- **Listing**: NASDAQ

- **Country or territory**: Canada

- **Business scope**: Non-viral genetic medicines

- **ISIN**: CA29286X1015

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ENGN/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/engene-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "enGene Therapeutics (ENGN) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/engene-therapeutics/